# AF Cardioversion Anticoagulation

For elective cardioversion of atrial fibrillation lasting 48 hours or longer or of uncertain duration, establish uninterrupted therapeutic anticoagulation for 3 weeks or exclude intracardiac thrombus by imaging, then continue anticoagulation for at least 4 weeks after restoration of sinus rhythm.

**Clinical question:** How should anticoagulation and imaging be used to prevent thromboembolism around atrial fibrillation cardioversion?

Updated: 2026-09-15T21:53:15.765739+00:00

## What matters in practice
- For elective cardioversion when AF duration is 48 hours or longer, use 3 weeks of uninterrupted therapeutic anticoagulation or preprocedural imaging that excludes intracardiac thrombus. [15]
- Establish therapeutic anticoagulation before electrical or pharmacologic cardioversion and continue it without interruption for at least 4 weeks afterward. [15]
- If imaging identifies left atrial appendage thrombus, defer cardioversion, give therapeutic anticoagulation for 3 to 6 weeks, and repeat imaging before reconsidering cardioversion. [15]
- DOACs are reasonable alternatives to vitamin K antagonists and may be preferred when not contraindicated because therapeutic effect is rapid and treatment continuity is more reliable. [15]
- A negative TEE does not eliminate the need for post-cardioversion anticoagulation because atrial stunning and early recurrence contribute to postprocedure thromboembolic risk. [15][20]

## Classify AF duration before scheduling elective cardioversion

Duration and anticoagulation continuity determine whether elective cardioversion can proceed.

For AF documented as lasting 48 hours or longer, use either of two pathways before elective electrical or pharmacologic cardioversion: uninterrupted therapeutic oral anticoagulation for 3 weeks, or imaging to exclude intracardiac thrombus. The thromboembolic precautions apply equally to pharmacologic and electrical cardioversion. [15]

Treat an uncertain onset time as a thrombus-risk scenario rather than relying on symptom onset alone. Contemporary practice commonly uses TEE to exclude left atrial or left atrial appendage thrombus when expedited cardioversion is needed and adequate preceding anticoagulation has not been completed. [3][4][15]

Do not use successful restoration of sinus rhythm as a reason to abbreviate anticoagulation. Cardioversion can embolize pre-existing thrombus and is followed by atrial mechanical dysfunction, or atrial stunning, and a transient prothrombotic state. [15]
- Elective AF cardioversion at 48 hours or longer: document either 3 weeks of uninterrupted therapeutic anticoagulation or imaging excluding intracardiac thrombus. [15]
- For an expedited strategy, obtain preprocedural imaging rather than proceeding on the basis of short-lived symptom reporting. [3][15]
- Apply the same pericardioversion thromboembolic strategy to chemical and electrical cardioversion. [15]

*Anticoagulation pathways for elective AF cardioversion. [15]*

| Clinical situation | Action before cardioversion | Action after cardioversion |
| --- | --- | --- |
| AF duration at least 48 hours | Complete 3 weeks of uninterrupted therapeutic anticoagulation, or perform imaging to exclude intracardiac thrombus. [15] | Continue therapeutic anticoagulation without interruption for at least 4 weeks. [15] |
| AF onset uncertain | Use the same 3-week anticoagulation or imaging-exclusion pathway before elective cardioversion. [3][15] | Continue therapeutic anticoagulation without interruption for at least 4 weeks. [15] |
| Intracardiac or LAA thrombus found | Defer cardioversion; institute therapeutic anticoagulation for 3 to 6 weeks and repeat imaging. [15] | Proceed only after repeat imaging informs the decision; maintain anticoagulation as indicated. [15] |

## Choose a therapeutic anticoagulant that can be maintained without interruption

The procedural requirement is continuous therapeutic anticoagulation, not a specific rhythm-control modality.

DOACs are accepted alternatives to vitamin K antagonists for thromboprophylaxis around cardioversion. In patients without a contraindication to DOAC therapy, their rapid onset, reliable maintenance of therapeutic effect, and ease of continuation make them a preferred practical option in the ACC/AHA/ACCP/HRS guideline discussion. [15]

If warfarin is used, ensure therapeutic anticoagulation rather than counting calendar time alone. The cardioversion literature describes warfarin therapy with therapeutic INR 2.0 to 3.0; interruption or subtherapeutic anticoagulation undermines the conventional delayed-cardioversion pathway. [21][22]

Do not substitute aspirin for therapeutic anticoagulation when cardioversion-related embolic protection is required. Adjusted-dose warfarin is substantially more efficacious than aspirin for stroke prevention in AF, and current cardioversion guidance specifies therapeutic anticoagulation before and after the procedure. [9][15]
- Select a DOAC when clinically suitable and when adherence can be assured through the pre- and post-cardioversion intervals. [15]
- For warfarin, verify that anticoagulation is therapeutic; INR 2.0 to 3.0 is the described therapeutic range. [21][22]
- Plan anticoagulant access and adherence before scheduling cardioversion because the 4-week postprocedure course should not be interrupted. [15]

*Anticoagulant considerations around AF cardioversion. [15][21][22]*

| Option | Practical pericardioversion use | Key limitation |
| --- | --- | --- |
| DOAC | May be used for cardioversion thromboprophylaxis and may be preferred when not contraindicated because therapeutic effect is rapid and continuation is straightforward. [15] | Requires reliable uninterrupted use throughout the planned strategy. [15] |
| Warfarin | Use as therapeutic anticoagulation; cardioversion literature describes a therapeutic INR of 2.0 to 3.0. [21][22] | A subtherapeutic INR or interruption prevents reliance on a completed therapeutic-anticoagulation pathway. [21] |

## Use TEE when cardioversion cannot wait for 3 weeks of anticoagulation

TEE changes management only if it determines whether cardioversion can proceed safely.

TEE-guided cardioversion is the alternative to waiting through the 3-week anticoagulation interval when AF is 48 hours or longer or onset is uncertain. A study of anticoagulated AF/AFL populations found a mean-weighted left atrial thrombus prevalence of 2.73%, emphasizing that anticoagulation exposure lowers but does not abolish thrombus risk. [12][15]

Use heightened caution in patients with nonparoxysmal AF/AFL or CHA2DS2-VASc score of 3 or greater. In the cited systematic review, left atrial thrombus prevalence was 4.81% in nonparoxysmal versus lower prevalence in paroxysmal AF/AFL, and 6.31% among those with CHA2DS2-VASc scores of 3 or greater. [12]

If TEE excludes intracardiac thrombus, cardioversion may proceed under therapeutic anticoagulation, but continue anticoagulation for at least 4 weeks afterward. A negative study addresses pre-existing thrombus; it does not prevent embolic risk related to post-cardioversion atrial stunning or early AF recurrence. [15][20]
- Use TEE to enable expedited cardioversion when the preceding 3-week uninterrupted-anticoagulation requirement has not been met. [15]
- Do not regard a negative TEE as a reason to omit the 4-week post-cardioversion anticoagulation interval. [15]
- Anticipate greater yield for TEE in nonparoxysmal AF/AFL and in CHA2DS2-VASc score 3 or greater. [12]

*How TEE findings change the cardioversion plan. [12][15]*

| TEE result | Interpretation | Next action |
| --- | --- | --- |
| No intracardiac thrombus | Permits an expedited preprocedure strategy when therapeutic anticoagulation is established. [15] | Proceed with cardioversion if otherwise appropriate; continue therapeutic anticoagulation for at least 4 weeks. [15] |
| LAA or other intracardiac thrombus | Cardioversion-related embolic risk remains unacceptable. [15] | Defer cardioversion; give therapeutic anticoagulation for 3 to 6 weeks, then repeat imaging. [15] |
| No thrombus after prior 3 weeks of anticoagulation | Residual thrombus is uncommon but not absent in anticoagulated populations. [12] | Proceed according to the planned pathway and preserve uninterrupted postprocedure anticoagulation for at least 4 weeks. [15] |

## Defer cardioversion when left atrial appendage thrombus is detected

A detected thrombus changes the immediate objective from rhythm restoration to thrombus resolution.

When pre-cardioversion imaging detects LAA thrombus, do not proceed with cardioversion. Institute therapeutic anticoagulation for at least 3 to 6 weeks and repeat imaging before reconsidering cardioversion. [15]

This repeat-imaging step is clinically consequential because left atrial thrombus can persist despite guideline-directed anticoagulation. Across studies of patients treated continuously for at least 3 weeks, mean-weighted prevalence was 2.73%; prevalence was higher in nonparoxysmal AF/AFL and in patients with CHA2DS2-VASc score 3 or greater. [12]

Reassess the urgency of rhythm restoration while thrombus is treated. If cardioversion is no longer needed because symptoms or ventricular response are acceptable, avoid exposing the patient to a repeat procedure solely to document sinus rhythm; if cardioversion remains planned, use repeat imaging to determine whether the thrombus-related procedural barrier has resolved. [15]
- Detected LAA thrombus: defer cardioversion. [15]
- Treat with therapeutic anticoagulation for 3 to 6 weeks before repeat imaging. [15]
- Use repeat imaging—not elapsed time alone—to reassess candidacy for cardioversion after a documented thrombus. [15]

## Maintain anticoagulation for at least 4 weeks after cardioversion

The postprocedure interval is required even when preprocedure imaging is negative.

Therapeutic anticoagulation should be established before cardioversion and continued without interruption for at least 4 weeks afterward. This recommendation applies to AF cardioversion regardless of whether the patient reached the procedure through 3 weeks of anticoagulation or through an imaging-guided strategy. [15]

The early post-cardioversion period is a high-risk interval: thromboembolic events are concentrated during the first month and particularly within the first 10 days in reported clinical summaries. The biologic rationale includes atrial stunning after sinus rhythm restoration, possible embolization of previously present thrombus, early AF recurrence, and a transient prothrombotic state. [15][20]

At the end of the mandatory 4-week interval, make the longer-term anticoagulation decision separately from the cardioversion decision, based on the patient's ongoing AF-related thromboembolic risk and clinical context. Do not let apparent maintenance of sinus rhythm alone substitute for longitudinal stroke-prevention assessment. [10][16]
- Continue therapeutic anticoagulation for a minimum of 4 weeks after electrical or pharmacologic cardioversion. [15]
- Protect adherence especially during the first 10 days and throughout the first month, when post-cardioversion embolic events are concentrated. [20]
- Reassess the indication for longer-term anticoagulation after the pericardioversion minimum has been completed. [10][16]

## Common questions

### Does a negative TEE eliminate the need for 4 weeks of anticoagulation after cardioversion?

No. A negative TEE excludes visualized pre-existing intracardiac thrombus but does not remove risk from post-cardioversion atrial stunning, early recurrence, and transient prothrombotic changes; continue therapeutic anticoagulation for at least 4 weeks. [15][20]

### What should be done if a left atrial appendage thrombus is found before cardioversion?

Defer cardioversion, administer therapeutic anticoagulation for at least 3 to 6 weeks, and repeat imaging before reconsidering cardioversion. [15]

## References
1. Supplementary appendix - The Lancet — www.thelancet.com — https://www.thelancet.com/cms/10.1016/S0140-6736(16)31474-X/attachment/f977242e-5cb9-41d5-8cf0-7e83cc4bfce9/mmc1.pdf
2. Direct oral anticoagulants: evidence and unresolved issues — www.thelancet.com — https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(20)32439-9.pdf
3. Identifying Patients at High Risk of Left Atrial Appendage Thrombus Before Cardioversion: The CLOTS‐AF Score — www.ahajournals.org — https://www.ahajournals.org/doi/full/10.1161/JAHA.122.029259?doi=10.1161%2FJAHA.122.029259
4. Preprocedural Multimodality Imaging in Atrial Fibrillation | Circulation — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/CIRCIMAGING.122.014386
5. 2014 AHA/ACC/HRS Guideline for the Management of Patients With ... — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/cir.0000000000000041
6. Identifying Patients at High Risk of Left Atrial Appendage Thrombus ... — www.ahajournals.org — https://www.ahajournals.org/doi/pdf/10.1161/JAHA.122.029259
7. Management of Newly Detected Atrial Fibrillation: A Clinical Practice ... — www.acpjournals.org — https://www.acpjournals.org/doi/10.7326/0003-4819-139-12-200312160-00011
8. Atrial Fibrillation | Annals of Internal Medicine - ACP Journals — www.acpjournals.org — https://www.acpjournals.org/doi/10.7326/AITC201703070
9. Antithrombotic Therapy To Prevent Stroke in Patients with Atrial ... — www.acpjournals.org — https://www.acpjournals.org/doi/10.7326/0003-4819-131-7-199910050-00003
10. Analysis of The 2024 ESC/EACTS Guidelines For The Management ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S1053077024009170
11. Trigger-induced atrial fibrillation for the hospitalist: a review — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0953620526001810
12. Prevalence of Left Atrial Thrombus in Anticoagulated Patients With Atrial Fibrillation — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0735109721047896
13. Spotlight on the 2024 ESC/EACTS management of atrial fibrillation guidelines: 10 novel key aspects — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC11666470
14. Clinical Practice Guideline: Preventive Measures and Treatment Options for Atrial Fibrillation — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC12580842
15. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC11104284
16. 2024 ESC Guidelines for the management of atrial fibrillation — www.escardio.org — https://www.escardio.org/guidelines/clinical-practice-guidelines/all-esc-practice-guidelines/atrial-fibrillation
17. A comparative review of current international atrial fibrillation guidelines from a primary care perspective — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC12258508
18. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines - PubMed — pubmed.ncbi.nlm.nih.gov — https://pubmed.ncbi.nlm.nih.gov/38033089
19. Atrial Fibrillation - StatPearls - NCBI Bookshelf - NIH — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK526072
20. Cardioversion in Atrial Fibrillation - American College of Cardiology — www.acc.org — https://www.acc.org/education-and-meetings/patient-case-quizzes/cardioversion-in-atrial-fibrillation
21. Anticoagulation in Atrial Fibrillation Cardioversion: What Is Crucial to Take into Account - PMC — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8348761
22. Pharmacological Cardioversion - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/sites/books/NBK470536
23. [PDF] Atrial fibrillation: diagnosis and management | NICE — www.nice.org.uk — https://www.nice.org.uk/guidance/ng196/resources/atrial-fibrillation-diagnosis-and-management-pdf-66142085507269
24. Atrial fibrillation: diagnosis and management | Guidance - NICE — www.nice.org.uk — https://www.nice.org.uk/guidance/ng196/chapter/Recommendations

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.